The overall poor prognosis observed in these patients suggests that the adverse clinical impact of iAMP21 overrides the presumably better prognosis associated with ETV6-RUNX1 in B-ALL. This evidence concerns the gene ETV6 and precursor B-cell acute lymphoblastic leukemia.